Please enable JavaScript to view this page correctly
Immune response_Bacterial infections in normal airways
Cytokine Inflammatory Panel by Flow Cytometry (CBA) - Can include 1 or all: IL-1 Beta, TNF alpha, IL-6, IL-8, IL-10 and IL-12 (p70) IL-6 IL-6, Interleukin 6 IL-6 s Receptor Luminex Bio-Rad Pro Human Cytokine 10-Plex Panel: IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, TNF alpha and IFN gamma Cytokine Inflammatory Panel by Flow Cytometry (CBA) - Can include 1 or all: IL-1 Beta, TNF alpha, IL-6, IL-8, IL-10 and IL-12 (p70) IL-1B, Human Interleukin 1 Beta Luminex Bio-Rad Pro Human Cytokine 10-Plex Panel: IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, TNF alpha and IFN gamma Cytokine TH1/TH2 Panel by Flow Cytometry (CBA) - Can included 1 or all: TNFalpha, IFN gamma, IL-2, IL-4, IL-5 and IL-10 Interferon Gamma Luminex Bio-Rad Pro Human Cytokine 10-Plex Panel: IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, TNF alpha and IFN gamma
Provided by
Thomson Reuters
Map Legend
The upper airways represent a primary site for the introduction of pathogenic
microorganisms from inspired air. The ciliated epithelium features several powerful
mechanisms for prevention of colonization by inhaled bacteria, thus the lower respiratory
tract usually remains sterile. Toll-like receptors (TLRs) play a key role in facilitating
the innate immune response to bacterial antigens [1 ].
Toll-like receptors (TLRs) belong to a family of transmembrane proteins that can
recognize and discriminate a diverse array of microbial antigens. Following their
activation by specific bacterial ligands, TLRs initiate intracellular signaling cascades
that culminate in the activation of transcription factors and ultimately lead to
activation of pro-inflammatory gene expression (acute inflammatory response ). Epithelial cells content of the airways provide both a physical barrier to
infection and an active defense mechanism against invading microoranisms [2 ].
TLR2 is the predominant TLR expressed on
the apical cell surface, with other TLRs (TLR1 , TLR4 and
TLR5 ) residing mainly intracellularly.
However, in inflamed lung following stimulation with bacterial ligands
TLR5 and TLR4 can be mobilized to the apical surface [2 ].
All TLRs, as well as IL-1RI , induce the
canonical pathway of NF-kB activation which
consists of MyD88 / IRAK4 and IRAK1/2 /
TRAF6 / TAB1
and TAB2 / TAK1(MAP3K7) / NIK(MAP3K14) /
IKK (cat) / I-kB / NF-kB cascade [2 ], [3 ], [4 ]. TLR2 and TLR4 signaling
pathways also require an additional adaptor TIRAP (Mal) [5 ], [6 ].
TLR signaling and NF-kB
activation are commonly involved in the
up-regulation of chemotactic molecules and cytokines (such as Interleukins
IL-1 beta , IL-6 and IL-8 ), production of
mediators of innate immune response (IFN-gamma and NO that is
synthesized by inducible nitric oxide synthase (iNOS ), enhanced expression of antimicrobial peptides (such as
Beta-defensin 2 ). IL-1 beta signaling, in turn, regulates the levels of
CFTR [7 ], [8 ].
Of all the TLRs, TLR2 in conjunction with
TLR1 recognizes the broadest repertoire of
ligands, such as Lipoteichoic acid (LTA) and Glycopeptide (peptidoglycan, PGN) from gram positive bacteria followed by
NF-kB activation and interleukin production
[2 ], [9 ], [10 ]. TLR5
is able to recognize Flagellin
(from both gram positive and gram negative bacteria), and also stimulate
NF-kB signaling [1 ], [11 ], [12 ].
Pseudomonas aeruginosa has been shown to signal through TLR4 / MD-2 /
CD14 complex with its LPS moiety [13 ], [14 ]. Although
TLR4 is expressed in airway epithelial cells,
it does not appear to be prominently involved in signaling of P. aeruginosa presented at
the apical surface of airway epithelial cells [1 ], [2 ], [15 ], [16 ]. The low level of MD-2 expression is also proposed to limit the responses of human airway
epithelia to endotoxin stimulation [17 ].
TLR2 can also mediate Beta-defensin 2 expression via NF-kB activation in response to bacterial antigens in human airway
epithelia [18 ], thus promoting an effective immune response
[1 ].
CFTR is a chloride channel that regulates
chloride transport, fluid hydration and mucociliary clearance in the lung, thus
preventing the bacterial growth in normal airways [1 ], [19 ], [20 ]. Normal CFTR promotes a rapid
expression of FasL(TNFSF6) and FasR(CD95) , as well as an apoptotic response to P. aeruginosa infection.
Mutant deltaF508 CFTR cells are characterized by inhibited apoptosis and
delayed FasL(TNFSF6) and FasR(CD95) expression in response to infection [21 ].
Bacterial stimulation also leads to FasR(CD95) -dependent NF-kB
activation [2 ], [22 ]. Rapid release of IL-1 beta (most probably NF-kB-dependent) is enhanced in the presence of
functional CFTR , but not deltaF508 CFTR in
respiratory epithelial cells [22 ].
The inducible form of nitric oxide synthase (iNOS ) is expressed constitutively in normal human airway epithelium
[23 ]. Both NF-kB and
IFN-gamma signaling components are necessary
for normal iNOS expression.
IFN-gamma activates JAK1 and (JAK2 /
STAT1 signaling followed by
IRF1 and iNOS expression [24 ]. Activation of PIAS1 results in reduced IRF1 and iNOS expression in CF,
but not healthy, epithelial cells [24 ].
Objects list:
Beta-defensin 2
Beta-defensin 4A
CD14
Monocyte differentiation antigen CD14
CFTR
Cystic fibrosis transmembrane conductance regulator
FasL(TNFSF6)
Tumor necrosis factor ligand superfamily member 6
FasR(CD95)
Tumor necrosis factor receptor superfamily member 6
Flagellin
Bacterial flagellin
Glycopeptide
I-kB
I-kappaB Protein group
IFN-gamma
Interferon gamma
IKK (cat)
IKK (cat) Complex
IL-1 beta
Interleukin-1 beta
IL-1RI
Interleukin-1 receptor type 1
IL-6
Interleukin-6
IL-8
Interleukin-8
IRAK1/2
Interleukin-1 receptor-associated kinases 1/2 Protein group
IRAK4
Interleukin-1 receptor-associated kinase 4
IRF1
Interferon regulatory factor 1
JAK1
Tyrosine-protein kinase JAK1
JAK2
Tyrosine-protein kinase JAK2
LPS
Chemical IUPAC name lipopolysaccharide
MD-2
Lymphocyte antigen 96
MyD88
Myeloid differentiation primary response protein MyD88
NF-kB
NF-kB Group of complexes
NIK(MAP3K14)
Mitogen-activated protein kinase kinase kinase 14
NO
Chemical IUPAC name Nitric oxide
PIAS1
E3 SUMO-protein ligase PIAS1
STAT1
Signal transducer and activator of transcription 1-alpha/beta
TAB1
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
TAB2
TGF-beta-activated kinase 1 and MAP3K7-binding protein 2
TAK1(MAP3K7)
Mitogen-activated protein kinase kinase kinase 7
TIRAP (Mal)
Toll/interleukin-1 receptor domain-containing adapter protein
TLR1
Toll-like receptor 1
TLR2
Toll-like receptor 2
TLR4
Toll-like receptor 4
TLR5
Toll-like receptor 5
TRAF6
TNF receptor-associated factor 6
iNOS
Nitric oxide synthase, inducible
Gomez MI, Prince A
Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis.
Current opinion in pharmacology 2007 Jun;7(3):244-51
Greene CM, McElvaney NG
Toll-like receptor expression and function in airway epithelial cells.
Archivum immunologiae et therapiae experimentalis 2005 Sep-Oct;53(5):418-27
Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy TF, Lim DJ, Li JD
Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells.
Proceedings of the National Academy of Sciences of the United States of America 2001 Jul 17;98(15):8774-9
Dziarski R, Gupta D
Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes.
Journal of endotoxin research 2000;6(5):401-5
Takeda K, Akira S
Microbial recognition by Toll-like receptors.
Journal of dermatological science 2004 Apr;34(2):73-82
Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'neill SJ, McElvaney NG
TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells.
Journal of immunology (Baltimore, Md. : 1950) 2005 Feb 1;174(3):1638-46
Brouillard F, Bouthier M, Leclerc T, Clement A, Baudouin-Legros M, Edelman A
NF-kappa B mediates up-regulation of CFTR gene expression in Calu-3 cells by interleukin-1beta.
The Journal of biological chemistry 2001 Mar 23;276(12):9486-91
Cafferata EG, Guerrico AM, Pivetta OH, Santa-Coloma TA
NF-kappaB activation is involved in regulation of cystic fibrosis transmembrane conductance regulator (CFTR) by interleukin-1beta.
The Journal of biological chemistry 2001 May 4;276(18):15441-4
Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A, Prince A
Toll-like receptors in normal and cystic fibrosis airway epithelial cells.
American journal of respiratory cell and molecular biology 2004 Jun;30(6):777-83
Shuto T, Furuta T, Oba M, Xu H, Li JD, Cheung J, Gruenert DC, Uehara A, Suico MA, Okiyoneda T, Kai H
Promoter hypomethylation of Toll-like receptor-2 gene is associated with increased proinflammatory response toward bacterial peptidoglycan in cystic fibrosis bronchial epithelial cells.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006 Apr;20(6):782-4
Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.
Nature 2001 Apr 26;410(6832):1099-103
Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM
Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5.
Infection and immunity 2005 Nov;73(11):7151-60
Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI
Human Toll-like receptor 4 recognizes host-specific LPS modifications.
Nature immunology 2002 Apr;3(4):354-9
Backhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A
Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications.
Microbes and infection / Institut Pasteur 2003 Oct;5(12):1057-63
Becker MN, Diamond G, Verghese MW, Randell SH
CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium.
The Journal of biological chemistry 2000 Sep 22;275(38):29731-6
Sadikot RT, Blackwell TS, Christman JW, Prince AS
Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.
American journal of respiratory and critical care medicine 2005 Jun 1;171(11):1209-23
Jia HP, Kline JN, Penisten A, Apicella MA, Gioannini TL, Weiss J, McCray PB Jr
Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2.
American journal of physiology. Lung cellular and molecular physiology 2004 Aug;287(2):L428-37
Wang X, Zhang Z, Louboutin JP, Moser C, Weiner DJ, Wilson JM
Airway epithelia regulate expression of human beta-defensin 2 through Toll-like receptor 2.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003 Sep;17(12):1727-9
Rowe SM, Miller S, Sorscher EJ
Cystic fibrosis.
The New England journal of medicine 2005 May 12;352(19):1992-2001
Dubin PJ, McAllister F, Kolls JK
Is cystic fibrosis a TH17 disease?
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2007 Jun;56(6):221-7
Cannon CL, Kowalski MP, Stopak KS, Pier GB
Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator.
American journal of respiratory cell and molecular biology 2003 Aug;29(2):188-97
Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB
Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.
Infection and immunity 2007 Apr;75(4):1598-608
Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC
Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo.
Proceedings of the National Academy of Sciences of the United States of America 1995 Aug 15;92(17):7809-13
Kelley TJ, Elmer HL
In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium.
The Journal of clinical investigation 2000 Aug;106(3):403-10
Developed by WaveAccess